New combo therapy aims to boost surgery success in pancreatic cancer

This study tests a combination of chemotherapy drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin), an immunotherapy drug (adebrelimab), and radiation before surgery for people with pancreatic cancer that is either removable or borderline removable but has risk factors. The goal is to see if this approach helps more tumors be completely removed and improves survival. About 37 participants will receive this treatment over several weeks before surgery.